Novo Nordisk files for regulatory approval of liraglutide 3 mg for the treatment of obesity
2013-12-20 · Novo Nordisk A/S · original novonordisk.com ↗
Bagsværd, Denmark, 20 December 2013 - Novo Nordisk today announced two separate regulatory submissions for a 3 mg dose of liraglutide, a once-daily human GLP-1 analogue, as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity, or who are overweight with comorbidities. The company filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) and a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA). Further information Media: Mike Rulis +45 4442 3573 [email protected] Ken Inchausti (US) +1 609 514 8316 [email protected] Investors: Kasper Roseeuw Poulsen +45 3079 4303 [email protected] Frank Daniel Mersebach +45 3079 0604 [email protected] Lars Borup Jacobsen +45 3075 3479 [email protected] Daniel Bohsen +45 3079 6376 [email protected] Jannick Lindegaard (US) +1 609 235 8567 [email protected] Company announcement No 78 / 2013
The release as fetched from its publisher. novonordisk.com ↗